Clinical trial
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting…
NCT00395317 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00395317 |
|---|---|
| Title | Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) |
| Official title | Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug, Other |
| Interventions | Placebo, Firategrast 150 mg, Firategrast 300 mg |
| Enrollment | 343 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | Nov 2, 2006 |
| Last update posted | Apr 9, 2012 |
| Countries | Australia, Austria, Canada, Finland, France, Germany, Italy, Netherlands, New Zealand, Norway, Poland, Russia and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: